Cognitive and motor development in HIV infected children : a systematic  review by Kgomo, Gretta Tumelo
 i 
 
COGNITIVE AND MOTOR DEVELOPMENT IN HIV INFECTED 
CHILDREN:  A SYSTEMATIC REVIEW 
 
 
 
 
 
Gretta Tumelo Kgomo 
 
 
Thesis presented in partial fulfilment of the requirements for the degree of Masters of 
Nursing Science in the Faculty of Health Sciences at the University of Stellenbosch 
 
 
 
 
Supervisor: Mr Oswell Khondowe 
Faculty of Health Sciences 
Division of Nursing 
 
 
 
 
 
 0DUFK
 
ii 
 
 
DECLARATION 
 
By submitting this thesis electronically, I declare that the entirety of the work contained 
therein is my own, original work, that I am the sole author thereof (save to the extent 
explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch 
University will not infringe any third party rights and that I have not previously in its 
entirety or in part submitted it for obtaining any qualification. 
 
Signature: ..........................................                                             Date: March 2012 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
iii 
 
Copyright © 201 University of Stellenbosch 
All rights reserved 
 
ABSTRACT 
 
The global epidemic of HIV continues with an estimated 2.2 million children under 15 
years of age worldwide living with HIV and 640 000 newly infected in 2004 (WHO, 
2009). HIV crosses the blood–brain barrier which may lead to neuronal damage and 
death. There is controversial evidence within available research on effects of HIV on 
cognitive and motor development in children because of the limitations imposed by 
study designs, study populations and study methodological quality.  
The aims of the review were: 
 To conduct a systematic review of published research to establish the effects and 
the prevalence of HIV infection on cognitive and motor development in children. 
 To critically appraise the methodological quality of published research regarding 
cognitive and motor development of HIV infected children. 
The objectives of the review were: 
 To assess evidence on the cognitive and motor development of HIV-1 infected 
children  
 To describe anthropometric outcomes including: weight for age, weight for 
height, height for age and head circumference in children with a HIV infection. 
 To assess the methodological quality of studies on the cognitive and motor 
development of HIV infected children. 
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The following databases were searched for identification of articles; MEDLINE, Google 
Scholar, AIDSTRIALS, AIDSLINE and CINHAL.  The search time frame included 
published works from inception to July 2011 without language restrictions.   
Analytical observational trials that assessed at least one outcome (cognitive or motor 
development or 1 of the anthropometric outcomes) between HIV positive and HIV 
negative children aged 5 years and below or children with a mean age of less than 5 
years were employed.  
Two review authors independently searched for eligible studies, evaluated 
methodological quality and extracted the data. Meta-analysis was carried out using Rev 
Man 5.1 using the risk ratio for categorical data and standard mean difference for 
continuous data. 
Fifteen studies with a total of 3 086 participants met the inclusion criteria. HIV infected 
children were 2.45 times at higher risk of developing cognitive developmental delay than 
HIV negative children (RR, 95% CI, 1.95, 3.07, P < 0.00001).  Infected children scored -
0.54 less than HIV negative children (SMD 95% CI, -0.70, -0.39, 97, p < 0.00001) for 
cognitive development and -0.68 in motor development (SMD 95% CI, -0.82, -0.55, p< 
0.00001). The risk of motor developmental delays was 2.95 times in HIV positive 
compared with HIV negative children (RR 95% CI, 2.19, 3.99, p < 0.00001). 
HIV infected children are slower in aspects of cognitive and motor development 
compared to their HIV negative counterparts. They also showed delays in 
anthropometric outcomes; weight for age and height for age. Study design influenced 
results of the studies with children scoring more on cross sectional than cohort studies. 
There is still need to develop culturally appropriate or standardise neurodevelopment 
tools as most African studies still rely on international tools. More evidence is needed on 
the effectiveness of HAART in reducing cognitive and motor delay. 
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OPSOMMING 
 
Die wêreldwye MIV epidemie duur voort met ongeveer 2.2 miljoen kinders onder 15 
jarige ouderdom wat wêreldwyd met MIV leef en 640 000 onlangs in 2004 geïnfekteerd 
(WHO, 2009). MIV strek oor die bloed-brein grens wat kan lei tot neuronale skade en 
die dood. Daar is kontroversiële bewys binne beskikbare navorsing oor die effek wat 
MIV het op kognitiewe en motoriese ontwikkeling in kinders, vanweë die beperkinge wat 
geplaas word deur studie ontwerpe, studie bevolkings en studie metodologiese 
kwaliteit. 
Die doelwitte van die oorsig is om 
 ‘n sistematiese oorsig van gepubliseerde navorsing te doen om sodoende die 
effek en voorkoms van MIV infeksie op kognitiewe en motoriese ontwikkeling by 
kinders vas te stel 
 ’n kritiese waardering van die metodologiese kwaliteit van gepubliseerde 
navorsing te doen ten opsigte van die kognitiewe en motoriese ontwikkeling van 
MIV geïnfekteerde kinders. 
Die doelwitte van die oorsig is om 
 assessering te doen van die bewyse van kognitiewe en motoriese ontwikkeling 
by MIV-1 geïnfekteerde kinders  
 antropometriese uitkomste te beskryf, insluitend: gewig vir ouderdom, gewig vir 
hoogte, hoogte vir ouderdom en omtrek van die hoof by kinders met ’n MIV 
infeksie 
 die metodologiese kwaliteit te assesseer van studies op die kognitiewe en 
motoriese ontwikkeling van MIV geïnfekteerde kinders. 
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Die volgende databasisse is nagevors vir die identifisering van artikels: MEDLINE, 
Google Scholar, AIDSTRIALS, AIDSLINE en CINHAL. Die tydraamwerk vir navorsing 
het gepubliseerde werk ingesluit vanaf aanvang tot Julie 2011 sonder taalbeperkings.   
Analitiese waarneembare toetse wat ten minste een uitkoms geassesseer het 
(kognitiewe of motoriese ontwikkeling of 1 van die antropometriese uitkomste) tussen 
MIV positiewe en MIV negatiewe kinders van 5 jarige ouderdom en jonger, of kinders 
met ’n gemiddelde ouderdom van minder as 5 jaar is betrek. 
Twee oorsig outeurs het onafhanklik vir geskikte studies gesoek, metodologies 
geëvalueer en data getrek. Meta-analise was uitgevoer deur gebruik te maak van Rev 
Man 5.1 met behulp van die risiko-ratio vir kategoriese data en die standaard 
gemiddelde verskil vir aaneenlopende data. 
Vyftien studies met ’n totaal van 3 086 deelnemers met die insluitingskriteria. MIV 
geïnfekteerde kinders het 2.45 keer ’n hoër risiko gehad om kognitiewe 
ontwikkelingsvertraging te ontwikkel as MIV negatiewe kinders (RR, 95% CI, 1.95, 3.07, 
P< 0.0000). Geïnfekteerde kinders het ’n -0.54 telling behaal, minder as MIV negatiewe 
kinders (SMD 95% CI, -0.70, -0.39,97 p < 0.00001) vir kognitiewe ontwikkeling en -0.68 
vir motoriese ontwikkeling (SMD 95% CI, -0.82, -0.55, p< 0.00001). Die risiko van 
motoriese ontwikkelingsvertragings was 2.95 keer by MIV positiewe in vergelyking met 
MIV negatiewe kinders (RR 95% CI, 2.19, 3.99. p < 0.00001). 
MIV geïnfekteerde kinders is stadiger in aspekte van kognitiewe en motoriese 
ontwikkeling in vergeyking met hulle MIV negatiewe eweknieë. Hulle het ook vertragings 
getoon in antropometriese uitkomste; gewig vir ouderdom en hoogte vir ouderdom. 
Studie ontwerpe het uitslae beïnvloed van die kinders wat ’n hoër telling behaal het met 
deursnee as in kohort studies. Daar is nog ’n behoefte om kultureel geskikte of 
gestandaardiseerde neuro-ontwikkelingsinstrumente te ontwikkel, omdat die meeste 
Afrika-studies nog steeds staat maak op internasionale instrumente. Meer bewyse is 
nodig aangaande die effektiwiteit van HAART om kognitiewe en motoriese vertraging te 
verminder. 
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Abstract 
Introduction: There is controversial evidence within available research on effects of HIV on 
cognitive and motor development because of the limitations imposed by study designs, study 
populations and study methodological quality. 
Aim: The main objective of the review was to assess evidence on cognitive and motor 
development in HIV-1 infected children in comparison to uninfected children. 
Methodology: The following databases were searched: MEDLINE, Google Scholar, 
AIDSTRIALS, AIDSLINE and CINHAL.  These databases were searched from their inception 
to July 2011 without language restrictions. Analytical observational trials that assessed at least 
one outcome (cognitive or motor development or 1 of the anthropometric outcomes) between 
HIV positive and HIV negative children aged 5 years and below or children with a mean age of 
less than 5 years were selected. Two review authors independently searched for eligible studies, 
evaluated methodological quality and extracted the data. Meta-analysis was carried out using 
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Rev Man 5.1 using the risk ratio for categorical data and standard mean difference for continuous 
data. 
Results: Fifteen studies with a total of 3 086 participants met the inclusion criteria. HIV infected 
children were 2.45 times at higher risk of developing cognitive developmental delay than HIV 
negative children (RR, 95% CI, 1.95, 3.07, P < 0.00001).  Infected children scored -0.54 less 
than HIV negative children (SMD 95% CI, -0.70, -0.39, 97, p < 0.00001) for cognitive 
development and -0.68 in motor development (SMD 95% CI, -0.82, -0.55, p< 0.00001). The risk 
of motor developmental delays was 2.95 times in HIV positive compared with HIV negative 
children (RR 95% CI, 2.19, 3.99, p < 0.00001). 
Conclusion: There appears to be an effect of HIV on motor, cognitive and anthropometric 
development in infected children. These results highlight the necessity of motor and cognitive 
interventions for HIV-infected children, focussing on motor and cognitive skills to improve their 
development and quality of life 
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Introduction 
 
Background   
The World Health Organization estimated that approximately 2.1 million children were living 
with the Human Immunodeficiency Virus (HIV) infection and in 2009, 370 000 children were 
newly infected worldwide (WHO, 2009).  Approximately 1.8 million children in sub-Saharan 
Africa are infected with HIV which accounts for 86% of HIV-infected children in the world 
(WHO, 2009). In 2006, HIV/AIDS claimed the lives of 380 000 children (Joint United Nations 
Programme on HIV/AIDS, 2006).  HIV infects cells of the immune system, destroying or 
impairing their function.  As the infection progresses, the immune system becomes weaker and 
the person becomes more susceptible to infections.  The most advanced stage of HIV infection is 
acquired immunodeficiency syndrome (AIDS).  HIV is transmitted through unprotected sexual 
intercourse (anal or vaginal), transfusion of contaminated blood, sharing of contaminated 
needles, and vertically transmitted during pregnancy (main mode of infection in young children), 
childbirth and breastfeeding (WHO, 2009).  
 
 
Description of the condition  
HIV involvement in the central nervous system has been reported since 1983 and HIV associated 
dementia (HAD) has been identified to be the major cause of cognitive and motor dysfunction 
observed in 50% of infected children (Price, Brew, Sidtis, Rosenblum, Scheck, & Cleary,1988, 
p. 4840).  HIV-1 penetrates the brain in the early phase of infection possibly by slipping through 
the blood brain barrier and targets and infects glial cells, from which it later secretes neurotoxins 
that lead to neuronal damage and death (Clifford, 2002, p. 540).  The magnitude of neuronal 
damage may be linked to the degree of clinical neurologic deficits (Dubé, Benton, Cruess, Evans, 
2005, p. 238). 
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HIV infection in the developing Central Nervous System (CNS) of children, known as HIV 
encephalopathy is characterized by either a progressive or static loss of previously acquired 
developmental milestones in cognitive, behavioural and motor development (Chase, Ware, 
Hittelman, Blasini, Smith, Llorente, 2000, p. 9).  It is common in rapid progressors with a 
positive test early and in utero infection during the last weeks of pregnancy, which is the period 
of fastest brain growth (Pearson, McGrath, Nozyce, Nichols, Raskino, Brouwers, 2000, p. 8).  
 
HAART is an effective therapy for the reduction of viral load, risk of resistance, increase in CD4 
count and reduction in mortality (Galetto-Lacour, Yerly, Perneger, Baumberger, Herschel, 
Perrin, 1996, p. 1338).  Childhood mortality is expected to decrease with the introduction of 
HAART and HIV long-term effects will be of utmost importance to health care providers. 
 
Elevated rates of moderate and severe cognitive impairment among children with HIV have been 
reported but are attributed to the lack or limited administration of HAART among the children 
examined (Thomaidis, Bertou, Critselis, Spoulou, Kafetzis, Theodoridou, 2010, p. 7).  Although 
HAART improves the functioning of HIV-1 infected children, some cases of CNS disease where 
children have scored below average cognitive functioning still exists (Martin, Wolters & Toledo-
Tamula, 2006, p. 649).  Kim and Rutstein (2010, p. 192), suggested that there is a possibility that 
antiretrovirals could be contributory factors to poor growth in some instances.  The pre and post 
HAART era identifies compromised cognitive and motor functioning among HIV infected 
children (Lindsey, Malee, Brouwers & Hughes, 2007 p. 687).  This suggests that despite 
improved treatment that even reduced neurologic complications, HIV infection still penetrates 
the central nervous system. Lindsey et al. (2007, p. 687) argue that neurodevelopment may be 
affected by genetic, health, disease, treatment, and/or psychosocial factors in the HAART era.   
 
Environmental factors affecting cognitive and motor development where children live include: 
poverty, violence and abuse, and prenatal drug abuse (Kullgren, Morris, Bachanas, Jones, 2004, 
p. 250).  Chase et al. (2000, p. 9) stated that there is no significant difference in cognitive and 
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motor performance in drug exposed and none exposed infants.  Nutritional deficiencies such as 
the lack of vitamin A, iodine, iron, inadequate caloric and protein intake affect both physical and 
cognitive development (Engle, Black, Behrman, de Mello, 2007, p. 230). 
  
The human brain growth velocity is at its peak at term and preterm delivery leads to a permanent 
reduction in final brain size (Cooke & Hughes, 2003, p. 486).  This may lead to an increased risk 
of cognitive motor and performance deficits (Chase et al., 2003, p. 8). 
 
A number of systematic reviews have been conducted to address developmental outcomes in 
children infected with HIV/AIDS.  However these studies have found it difficult to carry out a 
metanalysis on the effects of HIV on neurodevelopment due to diversity of measuring 
instruments and age of participants (Sherr, 2010, p. 397; Newman, 1995). In Sherr 92009, p. 
397) some studies compared HIV positive with seroreverters, whereas others compared both of 
these two with uninfected/unexposed control groups yet another group compared HIV positive 
with uninfected/unexposed control groups only. Some groups had sub analysis components 
according to severity of disease and presence of drug levels in the infant, which further 
compounded the comparability of studies. 
 
A review by Abubakar (2008, p. 885)  on seven studies did not draw firm conclusions on the 
effects and magnitude of HIV infection on the development of children in Sub Sahara Africa due 
to limited number of studies. The relationship between neurodevelopment and anthropometry has 
never been evaluated by previous reviews.  
 
Problem statement  
The global epidemic of HIV continues with an estimated 2.2 million children under 15 years of 
age worldwide living with HIV and 640 000 newly infected in 2004 (WHO, 2009).  HIV crosses 
the blood–brain barrier which may lead to neuronal damage and death. 
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There is controversial evidence within available research on the effects of HIV on cognitive and 
motor development because of the limitations imposed by study designs, study populations and 
study methodological quality.  The systematic review adds more evidence on the effects and 
prevalence of vertical HIV infection on cognitive and motor development in HIV infected 
children ages 5 years and below by summarizing all available evidence within the proposed 
stipulated criteria. The degree of risk of bias and confounding can be assessed by critical 
appraisal of methodological quality and a metanalysis in a systematic review which the previous 
reviews have not addressed. 
 
Significance of the Study  
As quality of life becomes a more essential concern in the management of HIV, better awareness 
of cognitive and motor manifestations of HIV is critical.  In an effort to guide clinicians and 
researchers with respect to the prevalence of HIV associated cognitive and motor effects on 
development, we conducted a quantitative systematic review of the research literature. 
 
Aims 
To conduct a systematic review of published research to establish the effects and the prevalence 
of HIV infection on cognitive and motor development in children. 
 
Objectives 
 To assess evidence on cognitive and motor development in HIV-1 infected children  
 To describe anthropometric outcomes including: weight for age, weight for height, height 
for age and head circumference in children with HIV infection. 
 To assess the methodological quality of studies on the cognitive and motor development 
of HIV infected children. 
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Ethical Review 
The final copy of the research protocol was presented to the Ethics committee of Stellenbosch 
University. Ethical review of the study was not deemed necessary because of the use of data that 
is available in the public domain. 
 
Methodology 
Criteria for considering studies for this review   
Types of studies  
Analytical observational trials that assessed at least one outcome (cognitive or motor 
development or one of the anthropometric outcomes) and comparing HIV positive and HIV 
negative children. The topic of study does not permit RCT’s since there is no intervention in the 
study therefore studies monitoring a developmental outcome and compare two groups of HIV 
infected and negative children will be included in this review. 
 
Participants 
HIV positive children compared with HIV negative children aged one month to five years or 
mean age of participants less than five years from Urban or rural setting.  
 
Types of outcome measures   
Primary outcomes   
Cognitive and motor development in children  
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Secondary outcomes 
Anthropometric outcomes: weight for age, weight for height, height for age and head 
circumference. 
  
Exclusion Criteria 
 Trials on children infected with HIV through blood transfusion to reduce bias on  the 
results by selecting vertically transmitted children who form the majority of the study 
population 
 Trials  on HIV with other co morbidities (haemophilia) since it will be difficult to relate 
deficits to HIV or haemophilia 
  Trials without a comparison group. 
 
Search methods for identification of studies   
Electronic searches   
The following databases were searched: MEDLINE, Google Scholar, AIDSTRIALS, AIDSLINE 
and CINHAL.  
The search included published works from inception to July 2011 without language restrictions.  
A specific search strategy to identify analytical observational studies was used in conjunction 
with medical subject headings and text words specific for cognitive and motor development, 
anthropometry and HIV.  When searching different databases, the search strategy was modified.  
The search for articles was conducted between 10th May and 30th July 2011. 
 
Search Terms: cognitive, motor, development, children, encephalopathy, Human 
immunodeficiency Virus (HIV), AIDS, neurodevelopment, height, weight, anthropometry, 
cohort, cross-sectional, experimental children, infants. 
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Search strategy for MEDLINE 
1. Cognitive 
2. Motor 
3. Cognit$ 
4. Physical 
5. Anthropomet$ 
6. Height 
7. Weight 
8. Encephalopathy 
9. Development$ 
10. Neurodevelopment 
11. Psychomotor 
12. Incapacity 
13. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 
14. HIV 
15. AIDS 
16. Human Immunodeficiency Virus 
17. Acquired Immunodeficiency Syndrome 
18. 13 AND 14 OR 15 OR 16 OR 17 
19. Child 
20. Children 
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21. Infants 
22. Toddler$ 
23. 18 AND 19 OR 20 OR 21 OR 22 
 
Searching of other sources  
Reference lists of all relevant articles and Google books on child development were searched for 
further relevant studies.  Proceedings and abstracts from AIDS conferences and global meetings 
were researched. Authors in the field of neurology and HIV/AIDS to assist with identifying 
relevant articles to be assessed for eligibility were contacted.  
 
Data Collection and Analysis 
Selection of studies 
The selection of studies for inclusion in a review is very imperative stage of the review process 
as it identifies all studies that need to be included in the review and if incorrectly done, relevant 
literature may be excluded. 
 
Eligibility 
Two reviewers: (GK, OK) independently assessed titles identified in the above search strategy.  
If a title was considered to be relevant, its abstract was reviewed to determine whether the article 
might meet predisposed eligibility criteria (see appendix 2 for a sample of eligibility form).  The 
eligibility form comprised of: type of study (Observational study), participants (HIV infected 
children compared with HIV negative children) and outcomes presented. An article that did not 
meet eligibility criteria was rejected. If the title or abstract leave room for doubt that the article 
cannot definitely be rejected, the full text of the article was obtained. Full text articles which did 
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not meet the inclusion criteria were excluded. If the article was not rejected, information from it 
may then be formally extracted using the data extraction form. Disagreements about the 
inclusion of studies were resolved by referring back to the original article and discussion until 
consensus was established between the two reviewers. 
 
Data extraction and management 
Characteristics of included studies were independently extracted by (GK, OK) using a 
standardised data extraction form for analytical observational studies (Appendix 5).  Data 
retrieved included: study design (cross-sectional, prospective cohort), study population (number 
of children, age)  and setting, scales used for assessments, outcomes, confounding factors 
controlled (preterm delivery, substance abuse,  socio- economic status, home and environment), 
number lost to follow up, and type of analysis (statistical methods, univariate/multivariate, 
adjusting for confounders).  Disagreements were resolved by discussion. 
 
Reliability and validity 
Inter -rater reliability, internal and external validity were utilised to ensure consistency, 
generalisation and the relationship between HIV infection and neurodevelopment in children 
aged 5 years and below. Study selection, data extraction methodological quality was conducted 
by two independent reviewers (GK, OK). Criteria for study inclusion/exclusion was 
predetermined and implemented. A pilot of two studies on the data extraction form was done and 
these pilots were included in the results section.  
 
 
 
Assessment of methodological quality  
Two reviewers (GK and OK) independently assessed the methodological quality of studies was 
assessed using the Newcastle Scale for Observational Studies (NOS) (Wells, Shea, O’Connell 
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Robertson, Peterson, Welch, et al.). A criterion was stipulated to GK and OS which items to 
award a star to a study before data extraction. The NOS and its stipulated criteria were piloted 
before being applied. A star was awarded if both reviewers gave an item a star and if there were 
doubts; reviewers discussed the item and a referred back to the article until consensus was 
reached. 
NOS comprises of three categories: selection, comparability and exposure/outcome. It was 
chosen mainly for this review because it contains separate questions for cohort and case control 
studies. It was developed based on threats to validity in nonrandomized studies; these 
specifically include selection of participants (generalizability or applicability), comparability of 
study groups, methods for outcome assessment (cohort studies) or ascertainment of exposure 
(case-control studies), adequacy of follow-up and inter-rater reliability. 
The selection category has four items; each item is scored by a star.  The outcome/ exposure 
categories have three items, each to be awarded with a star.  However, cross sectional studies 
were assessed for only two items in the exposure section as the same response item was removed 
due to its irrelevance to design in this review. 
A maximum of two stars can be given for the category of comparability.  Cross sectional studies 
were scored out of eight and cohort studies scored out of nine stars.  The table below shows the 
criteria used to award a star for studies in each numbered item. 
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Table 1: Newcastle-Ottawa Scale for Observational Studies (Scoring Criteria) 
 
 
 
Selection   Comparability   Outcome/Exposure 
Cross sectional studies (4 stars) (2 stars) (2 stars) 
1. HIV test for all HIV positive children and 
exclusion criteria given* 
2. Representativeness of the sample of HIV 
infected children in the community not by sample 
of convenience* 
3. Community controls used* 
4. Children were defined as healthy with absence 
of disease * 
Matched with age* controlling 
of any confounder (Socio 
economic status, preterm 
delivery, prenatal drug 
exposure, home and 
environment).* 
1.Blinded 
developmental 
assessment was done*  
2. The same scale was 
used to assess the two 
groups. * 
 
Cohort Studies (4 stars) (2 stars) (3 stars) 
1. Representativeness of HIV infected children in the 
community reason for exclusion specified and if the 
author stated that the sample represented the community 
* 
2. Participants were from the same community * 
3. An HIV test or record determined ascertainment of 
the exposure* 
4. An initial developmental assessment to demonstrate 
absence of developmental anomalies before enrolment* 
Matched with age* 
controlling of any 
confounder (Socio 
economic status, preterm 
delivery, prenatal drug 
exposure, home and 
environment).* 
1.Independent blind 
assessment or record 
linkage *  
2. Follow- up period of 
one  year or more*  
3. Dropout rate less than 
15% in HIV positive and 
HIV negative  groups* 
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Measures of treatment  
Data were analysed using Review Manager 5.1.  Dichotomous data were analysed with Mantel-
Haenszel methods and risk ratios with a 95% confidence interval.  Standardised mean difference 
(SMD) with 95% confidence intervals for continuous data was used. SMD was selected due to 
variability in rating scales for the assessment of cognitive and motor development.  
 
Assessment of heterogeneity 
 
A random effects method was used to easily identify heterogeneity with wider confidence 
intervals. Statistical heterogeneity was assessed by using a chi-squared test on N-1 degrees of 
freedom.  Inconsistency across the studies in the meta-analysis was quantified by means of the I² 
statistic.  
Heterogeneity was considered to be statistically significant if the p-value for the Chi squared test 
was < 0.10.  I²= 0 to 30 % was low heterogeneity, I² value of >30 to 60 moderate, >60 to 75 
substantial and >75% was regarded as considerable heterogeneity. 
 
 
Data synthesis 
All included articles were analysed by Review Manager (version 5.1) Cochrane software. Data 
from studies with similar participants, outcomes, and study designs were pooled in a meta-
analysis if there was no significant statistical heterogeneity. A fixed-effect model was employed 
if there was low heterogeneity (I² = 0 to 30) for the main effect outcomes. Where heterogeneity 
of more than 30% existed, the random-effects model was incorporated.   
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Subgroup analysis and investigation of heterogeneity 
A subgroup analysis was planned prior to the main analysis for primary outcomes only by study 
design and type of instrument used.  However, studies were stratified by study design (cohort 
and cross sectional) and a subgroup analysis of studies that used Bailey Scales was used to 
explore heterogeneity of >30% and examine direction of findings. 
 
 
Sensitivity analysis 
 
Sensitivity analysis to assess heterogeneity and to examine the direction of findings on cognitive 
and motor outcomes was planned in the protocol stage on studies that did not report blinding of 
the investigators and ARV/ HAART naïve studies. However sensitivity analysis was applied on 
anthropometric outcome: weight for age at the results stage to investigate heterogeneity. 
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Results 
 
 
 
 
Figure 1: Flowchart of the screening process  
Potentially relevant studies 
identified and screened for 
retrieval (n=336) 
Studies excluded, after reading 
titles (n=282)
Studies retrieved for more 
detailed evaluation (n=54) 
Potentially appropriate 
studies to be included in the 
systematic review and meta‐
analysis (n=20)                  
Studies included in systematic 
review (n=15) 
Studies excluded after reading abstracts : 
Reviews, Editorials, commentaries, studies 
not reporting cognitive and motor 
development and anthropometry, case 
reports, parenting guidelines, HIV exposed 
children but not infected  (n=34). 
(n =5) Studies excluded after authors 
did not respond to impute data (n = 4) 
and duplicate (n =1) 
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Search Results 
 
Figure 1 shows search results.  The search strategy initially retrieved 336 titles of which 282 
publications were excluded based on the relevance of the title.  Following the exclusion of 
irrelevant titles, 54 abstracts were screened for eligibility.  Thirty four publications were 
excluded after reading abstracts.  Only 20 potentially appropriate studies to be included in the 
systematic review remained.  We further excluded 5 studies (4 with missing data and 1 
duplicate).  Meta-analysis was performed on 15 studies. 
 
Description of included studies  
A total of 15 studies with a total of 3 086 (598 HIV positive and 2 488 HIV negative) 
participants met the inclusion criteria. Six studies were conducted in Africa, 6 USA, 1 Brazil, 1 
Europe and 1 in Haiti.  Three studies were cross sectional designs, 9 prospective and 3 
retrospective cohorts.  Five studies compared HIV positive with seroreverters, whereas 10 
compared HIV positive children with both uninfected and seroreverters control groups.  
Assessments were conducted in hospital settings by 14 studies, at home and (n=1).  
HIV positive group: All children in the HIV positive group were tested for HIV or the data 
available showed that they were known HIV cases.  
 
HIV negative group: Studies compared HIV positive (seropositive) children with either 
seroreverters (Exposed to HIV during pregnancy) or HIV negative (seronegative) or both.  In 
studies with more than two comparison groups, two comparison groups were chosen for this 
review. 
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Loss to Follow-up (LTFU): Loss to follow-up due to death ranged from 0% to 58% in the HIV 
positive group.  LTFU due to any other reasons ranged from 0% to 27 in HIV negative and 29% 
in HIV positive groups.  Antiretroviral treatment was not readily available when studies were in 
progress in 13 studies. However, loss to follow up did not affect the results of this review 
because first assessment was chosen in studies with more than 1 assessment when most 
participants were present. 
 
Diagnostic criteria: HIV-1 infection was diagnosed by confirmed antibody tests and the World 
Health Organisation staging of AIDS.  
 
Scales used 
Studies used seven varying neurological scales to evaluate developmental milestones in children: 
Bailey Scales of Infant Development (n= 8 studies), Kaufman Assessment Battery for Children 
(n=1), Denver Developmental Screening Test with Clinical Adaptive Test, (n=1), Snijders 
Oomen Nonverbal Intelligence Test–Revised (n=1), Wechsler Preschool and Primary Scales of 
Intelligence-Revised, (n =1) and the Kififi scale (n=1). 
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Table 2: Characteristics of Included Studies 
First author, 
Year, Country 
Study Design Participants + Setting Method used to test HIV  Age  
scales used 
1.Abubakar, 
2009        
Kenya  
Cross sectional 
Study 
31 HIV infected , 17 
HIV-seroreverters  and 
319  seronegative  
Examined @ home 
positive HIV antibody test 
when > 18 months or a 
polymerase chain reaction 
test if  < than 18 months  
Aged 6 to 35 
months. 
Kififi scale  
2. Aylward, 
1992.          
USA 
Prospective 
cohort 
 96 infants: 45, 
seronegative, 12 
seropositive  and 39 
Seroreverters hospital 
setting 
HIV antibody test  5.5 to 24 
months. 
BSID II 
3.Boivin, 1995   
Zaire 
Prospective 
Longitudinal 
cohort 
11 HIV infected, 15 
Seroreverters 15 control  
(hospital near Kimpese) 
HIV check blot Test  
 
HIV +: mean 
age: 54.8 SD: 
8.6 Control: 
46.2.SD: 12.6 
 K-ABC 
4.Chase, 2000 
USA 
Multicentre 
Prospective 
cohort 
421 infants: 77 HIV 
positive and 344 
Seroreverters                     
6 clinical centres 
Presence of 2 or more 
cultures of peripheral 
blood mononuclear cells 
positive for HIV-1   
From 7days till 
30 months.  
BSIDII 
5.Dobrova-
Krol, 2010 
Ukraine 
Cross Sectional 
Study 
Total: 64: 13 HIV+ 
institution-reared, 16 
negative institution-
reared, 16 HIV+ family-
reared and 19HIV 
negative family-reared 
children. 
Positive viral culture of 
polymerase chain reaction 
assay  
Mean :50.9 
months 
SON–R 
&theory of 
mind 
6.Drotar, 1997 
Uganda 
prospective  
cohort study 
 61 HIV positive infants, 
234 Seroreverters, and 
115 HIV negative  
HTV-1 enzyme 
immunoassay confirmed 
with Western Blot (WB) 
HTV-1 DNA polymerase 
Enrolled at birth 
for 24 months.  
BSID II 
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Old Mulago Hospital chain reaction (PCR) and 
(ICD) tests  
7.Fishkin, 2000 
USA 
Retrospective 
Cohort 
40 HIV infected and 40 
HIV negative children  
Hospital files and 
clinical programme 
Medical records Ages 3 to 
5years.  
WPPSI-R) 
8.Gay, 1995 
Haiti 
Prospective 
Cohort 
126 Children : 28 HIV 
infected and 98 
Seroreverted children 
from 18 months 
Clinical, immunologic, 
serologic, and virologic 
end points 
From birth till 
24 months. 
BSID 
9. Knight, 2000 
USA 
Retrospective 
cohort 
20 HIV infected and 25 
Seroreverters aged 3 to 
30 months old  
family based care in a 
hospital 
Positive  HIV antibodies 
after 18months        
 
3 till 30 months 
old. 
 
BSID 
10.Lindsey, 
2007 
USA 
Longitudinal 
prospective  
cohort study 
838 Seroreverters and 91 
HIV positive  
Hospital setting 
Positive HIV antibody 
>18months 
 
1month to 
3years. 
 
BSID 
11.McGrath, 
2006    
Tanzania 
Prospective 
Cohort  
276: 55HIV positive and 
221 seroreverters   
Muhimbi hospital 
Polymerase chain reaction 
(PCR) @>18months 
 
Birth till 24 
months.  
BSID-II 
12. Miller, 
1993 USA 
Retrospective 
cohort  
37 Seroreverted and 51 
HIV Positive children. 
Children’s Hospital  
setting 
ELISA and Western Blot 
analysis after 15 mo of 
age, or WHO clinical signs 
Mean: 21HIV + 
Mean: 
19control. 
Weight scale 
13. Msellati, 
2003 Rwanda 
prospective 
cohort study 
218 Seroreverters and 
HIV+ compared with 
218 seropositive infants.   
WHO clinical case 
definition of AIDS in 
children and HIV-1 
antibody serostatus > 15 
From birth till 
24 months.  
Modified 
Denver score  
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Hospital Setting months of age 
14. Tahan 2006 
Brazil 
progressive 
prospective and 
cross sectional 
88 HIV positive children 
and 84 Seroreverters          
Clinical Hospital of 
UFPR. 
Serological and/or 
virologic tests 
 
1month till 36 
months. 
CAT/CLAMS, 
DDST 
15. Van Rie , 
2007 Republic 
of Congo 
Cross sectional 
study 
35 HIV-infected, 35 
Seroreverters and 90 
seronegative 
Hospital setting 
Enzyme-linked 
Immunosorbent assay–
based 
 
Median: HIV + 
45.7, Reverters: 
45.6. 
BSID  
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Quality Assessment of included studies  
Studies with nine items and eight on the cross sectional in the Newcastle-Ottawa Scale were 
considered satisfactory and statistical analysis (multivariate or risk adjusted) deemed studies as 
of high methodological quality.  Only four studies did a multivariate analysis or other acceptable 
methods of adjusting to ensure that studies did not report biased results to minimize the potential 
for confounding.  Among cohort studies 1 study scored 9 stars, 6 scored 8 stars and 5 scored 7 
stars.  Among cross sectional studies 1 study scored a total score of 8 and the other 2 scored 7.  
Intent to treat was done in 11 studies and 10 studies blinded examiners.  In overall, studies were 
of moderate quality. 
 
Table 3: Quality of Included Studies (Newcastle for Observational Studies) 
 
Cross Sectional 
First Author Selection Comparability Exposure Total 
Abubakar               8 
Dobrova-
Krol 
             7 
Van Rie               7 
\ 
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Cohort studies  
First Author Selection Comparability Outcome Total 
stars 
Aylwald    6% LTFU 7 
Boivin     8 
Chase     Covariate in the modelling 
process.  High Quality 
3.8% LTFU and 
13HIV+  died 
8 
Fishkin      7 
Drotar    Stratified group means for home 
and environment.  High Quality  
7% LTFU 8 
Gay    3%LTFU, 56% died in 
HIV+ group and 1 in HIV  
8 
Knight     9 
Lindsey    Univariate analysis   
High Quality 
13%HIV: 6% HIV+ 
LFTU 
8 
Mc Grath
  
  11%LTFU. 27% 
:HIV+ 29%HIV- died 
7 
Miller     8 
Msellati    Analysis of variance for 
prematurity High Quality 
5.5%LTFU. 58% 
cumulative mortality 
7 
Tahan    24% loss of LTFU 7 
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Cognitive development  
A total of 12 studies; 1 with 2 subgroups (family and institutionally reared children) with a total 
of 2 206 participants (429 HIV positive and 1 777 HIV negative) reported sufficient data on 
cognitive development.  
 
Children with cognitive developmental delay 
Six studies reported on cases of cognitive development in HIV positive and negative children 
(Aylwald 1992; Drotar 1997; Gay 1995; McGrath 2006; Tahan 2006; Van Rie 2008).  Five of 
the studies used the BSID and 1 used the Clinical Adaptive Test.  A total of 908 children: 193 
HIV positive and 715 HIV negative children were analysed (Figure 2). HIV positive children 
were 2.45 times at higher risk of developing developmental delay than HIV negative children 
(95% CI, 1.95, 3.07, p < 0.00001).  Heterogeneity was not important: Chi² = 4.80, df = 5 (p = 
0.44); I² =0%. 
 
Study or Subgroup
1.1.1 cohort srudies
Aylwald et al., 1992
Drotar et al, 1997
Gay et al,1995
McGrath et al., 2005
Tahan et al, 2006
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 4.39, df = 4 (P = 0.36); I² = 9%
Test for overall effect: Z = 7.12 (P < 0.00001)
1.1.2 cross sectional studies
Van Rie et al, 2008
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 3.03 (P = 0.002)
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.80, df = 5 (P = 0.44); I² = 0%
Test for overall effect: Z = 7.69 (P < 0.00001)
Test for subgroup differences: Chi² = 0.36, df = 1 (P = 0.55), I² = 0%
Events
6
9
19
18
12
64
11
11
75
Total
12
58
28
68
16
182
11
11
193
Events
3
12
25
37
24
101
9
9
110
Total
43
211
98
259
84
695
20
20
715
Weight
2.8%
10.9%
23.4%
32.3%
16.1%
85.5%
14.5%
14.5%
100.0%
M-H, Fixed, 95% CI
7.17 [2.10, 24.50]
2.73 [1.21, 6.16]
2.66 [1.74, 4.06]
1.85 [1.13, 3.04]
2.63 [1.69, 4.08]
2.50 [1.94, 3.22]
2.12 [1.30, 3.44]
2.12 [1.30, 3.44]
2.45 [1.95, 3.07]
HIV positive HIV negative Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
HIV positive HIV negative  
 Figure 2: HIV positive and negative children with cognitive development delay  
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Cognitive quotient of HIV positive and negative children 
Six studies, 1 with 2 subgroups (family and institutionalised children) reported on cases of 
cognitive development in HIV positive and negative children (Boivin 1996; Chase 2000; Fishkin 
2000; Knight 2000; Tahan 2006; Dobrova- Krol 2010A; Dobrova- Krol 2010B; Lindsey 2007). 
Three of the studies used the BSID, K-ABC (n=1), WPPSI: (n=1), SON-R (n=1). A total of 1 
298 children (236 HIV positive and 1 062 HIV negative) were analysed. 
HIV infected children scored a significantly lower cognitive mean quotient than their HIV 
negative counterparts with a standard mean difference of -0.54 (SMD 95% CI, -0.70, -0.39, p = < 
0.00001) heterogeneity between studies was not important:  Chi² = 5.69, df = 6 (p = 0.46); I² = 
0%. 
Study or Subgroup
1.2.1 Cohort studies
Chase et al., 2000
Fishkin et al.,2000
knight et al., 2000
Lidsey et al., 2007
Boivin et al., 1995
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.59, df = 4 (P = 0.46); I² = 0%
Test for overall effect: Z = 6.53 (P < 0.00001)
1.2.2 Cross sectional studies
Dobrova-Krol et al, 2010B
Dobrova-Krol et al, 2010A
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 1.73, df = 1 (P = 0.19); I² = 42%
Test for overall effect: Z = 1.87 (P = 0.06)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 5.69, df = 6 (P = 0.46); I² = 0%
Test for overall effect: Z = 6.97 (P < 0.00001)
Test for subgroup differences: Chi² = 0.19, df = 1 (P = 0.66), I² = 0%
Mean
96.8
73.15
76.1
84
96
79.07
64
SD
19.2
13.86
26
15
10.3
16.9
14.32
Total
80
40
20
57
11
208
15
13
28
236
Mean
105
76.85
94.7
92
97.5
98.94
69.73
SD
15.2
10.54
22.3
12
18.6
19.59
21.28
Total
362
40
25
593
15
1035
16
11
27
1062
Weight
39.1%
12.0%
6.3%
31.1%
3.9%
92.4%
4.1%
3.6%
7.6%
100.0%
IV, Random, 95% CI
-0.51 [-0.76, -0.27]
-0.30 [-0.74, 0.14]
-0.76 [-1.37, -0.15]
-0.65 [-0.92, -0.38]
-0.09 [-0.87, 0.69]
-0.53 [-0.69, -0.37]
-1.06 [-1.81, -0.30]
-0.31 [-1.12, 0.50]
-0.70 [-1.43, 0.03]
-0.54 [-0.70, -0.39]
HIV positive HIV negative Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
HIV positive HIV negative  
Figure 3: Cognitive developmental mean quotient of HIV positive and negative children 
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Motor Development  
A total of 11 studies, 1 with 2 subgroups (gross motor and fine motor) and 2 822 participants 
(476 HIV positive and 2 346 HIV negative) reported sufficient data on motor development. 
 
Children with motor developmental delay 
Five studies (Aylwald 1992; Drotar 1997; Gay 1995; Mc Grath 2005; Van Rie 2008) reported on 
motor development in HIV positive and negative children. Five of 6 studies used Bailey Scales 
of infant development. A total of 886 children: 206 HIV positive and 680 HIV negative were 
analysed. 
HIV positive children were 2.95 times a risk of developing motor developmental delays than 
HIV negative children (RR, 95% CI, 2.95 2.19, 3.99, p = < 0.00001). There was a low defined 
heterogeneity between studies; Tau² = 0.02; Chi² = 5.82, df = 5 (p = 0.32): I² = 14%. 
Study or Subgroup
1.3.1 cohort studies
Aylwald et al., 1992
Drotar et al, 1997
Gay et al,1995
McGrath et al., 2005
Tahan et al, 2006
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 5.54, df = 4 (P = 0.24); I² = 28%
Test for overall effect: Z = 6.38 (P < 0.00001)
1.3.2 Cross sectional studies
Van Rie et al, 2008
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 3.24 (P = 0.001)
Total (95% CI)
Total events
Heterogeneity: Chi² = 5.82, df = 5 (P = 0.32); I² = 14%
Test for overall effect: Z = 7.07 (P < 0.00001)
Test for subgroup differences: Chi² = 0.30, df = 1 (P = 0.59), I² = 0%
Events
3
9
14
18
13
57
10
10
67
Total
12
58
28
67
30
195
11
11
206
Events
7
16
8
26
7
64
5
5
69
Total
45
211
98
260
46
660
20
20
680
Weight
8.9%
20.8%
10.7%
32.2%
16.7%
89.3%
10.7%
10.7%
100.0%
M-H, Fixed, 95% CI
1.61 [0.49, 5.30]
2.05 [0.95, 4.39]
6.13 [2.86, 13.10]
2.69 [1.57, 4.60]
2.85 [1.29, 6.31]
2.87 [2.08, 3.97]
3.64 [1.66, 7.95]
3.64 [1.66, 7.95]
2.95 [2.19, 3.99]
HIV positive HIV negative Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
HIV positive HIV negative  
Figure 4: Motor developmental delay in HIV positive and negative children 
Stellenbosch University http://scholar.sun.ac.za
27 
 
 
Six studies, 1 with 2 subgroups (gross motor and fine motor)                        
(Abubakar 2009; Chase 2000; Knight 2000; Lindsey 2007; Msellati 1993A; Msellati 1993B and 
Boivin 1995) had a total of 1 936 children (270 HIV positive and 1 666 HIV negative).  BSID 
was used by three studies, modified Denver scale (n=1), K-ABC (n=1), Kififi scale (n=1). 
HIV infected children scored a significantly lower mean quotient than that of HIV negative 
children with a Standard Mean Difference of -0.68 (SMD 95% CI, -0.82, -0.55, p< 0.00001). 
Heterogeneity was not important: Chi² = 5.80, df = 6 (p = 0.45); I² = 0%.   
However, there was substantial heterogeneity between subgroups of cohort and cross sectional 
studies: Test for subgroup differences: Chi² = 3.47, df = 1 (p = 0.06), I² = 71.2%. 
 
Study or Subgroup
1.4.1 cohort studies
Chase et al., 2000
knight et al., 2000
Lidsey et al., 2007
Msellati et al.,1993A
Msellati et al.,1993B
Boivin et al., 1995
Subtotal (95% CI)
Heterogeneity: Chi² = 2.33, df = 5 (P = 0.80); I² = 0%
Test for overall effect: Z = 8.70 (P < 0.00001)
1.4.2 Cross sectional studies
Abubakar et al.,2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 5.30 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 5.80, df = 6 (P = 0.45); I² = 0%
Test for overall effect: Z = 10.02 (P < 0.00001)
Test for subgroup differences: Chi² = 3.47, df = 1 (P = 0.06), I² = 71.2%
Mean
97.7
78.8
80
3.21
3
83
-0.91
SD
19.9
29.1
17
1.29
1.28
14.2
1.86
Total
78
20
57
33
40
11
239
31
31
270
Mean
108.3
94.6
89
3.83
3.54
115.2
0.08
SD
15.8
18.4
15
1
0.74
29.4
0.84
Total
359
25
593
169
186
15
1347
319
319
1666
Weight
28.9%
4.9%
23.8%
12.5%
14.9%
2.4%
87.4%
12.6%
12.6%
100.0%
IV, Fixed, 95% CI
-0.64 [-0.89, -0.39]
-0.65 [-1.26, -0.05]
-0.59 [-0.87, -0.32]
-0.59 [-0.96, -0.21]
-0.63 [-0.97, -0.28]
-1.29 [-2.15, -0.42]
-0.63 [-0.78, -0.49]
-1.02 [-1.39, -0.64]
-1.02 [-1.39, -0.64]
-0.68 [-0.82, -0.55]
HIV positive HIV negative Std. Mean Difference Std. Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
HIV positive HIV negative  
Figure 5 : Motor Developmental mean quotient in HIV positive and negative children 
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Anthropometric Outcomes 
 
Weight for age  
Four studies (Abubakar 2009; Boivin 1995; Dobrova-Krol 2010A; Dobrova-Krol 2010B; Miller 
1993), 1 with 2 subgroups (family and institutionalised children) with a total of 524 participants 
reported on weight for age. HIV positive children scored a significant lower mean weight for age 
quotient with a SMD of -0.55 compared to HIV negative children of the same age (SMD, 95% 
CI, 0.91, -0.20, p = 0.002). Heterogeneity was moderate: Chi² = 7.61, df = 4 (p = 0.11); I² = 47%.
 
Study or Subgroup
Abubakar et al.,2009
Boivin et al., 1995
Dobrova-Krol et al, 2010A
Dobrova-Krol et al, 2010B
Miller et al, 1993
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 7.61, df = 4 (P = 0.11); I² = 47%
Test for overall effect: Z = 3.05 (P = 0.002)
Mean
-2.12
13
-1.36
-1.15
2.89
SD
1.36
3.9
0.56
1.21
0.139
Total
31
11
13
15
52
122
Mean
-1.24
14.5
-0.81
-0.32
2.9
SD
1.08
3.4
0.61
0.99
0.108
Total
319
15
15
16
37
402
Weight
29.7%
13.9%
13.9%
15.3%
27.2%
100.0%
IV, Random, 95% CI
-0.79 [-1.17, -0.42]
-0.40 [-1.19, 0.39]
-0.91 [-1.69, -0.12]
-0.73 [-1.46, -0.00]
-0.08 [-0.50, 0.34]
-0.55 [-0.91, -0.20]
HIV positive HIV negative Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
HIV positive HIV negative
Figure 6: Weight for age among HIV positive and negative children 
 
Weight for height  
Boivin (1995) was the only study to report weight for height with 26 participants: 11 HIV 
positive and 15 HIV negative. There was no significant difference in weight for age for HIV 
infected children (SMD -0.43, 95% CI-1.22, 0.36 p = 0.28). 
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Height for age  
Two studies, 1 with 2 subgroups (family and institutionalised children)  reported height for age 
(Boivin 1995; Dobrova-Krol 2010 A; Dobrova-Krol B) with a total of 90 participants: 40 HIV 
positive and 50 HIV negative.  
HIV infected children had an SMD of -0.79 lower height for age than HIV negative (95% CI -
1.25, -0.33, p = < 0.0007).  Studies were homogenous: Tau² = 0.00; Chi² = 0.05, df = 2 (p = 
0.97); I² = 0%. 
Study or Subgroup
Boivin et al., 1995
Dobrova-Krol et al, 2010B
Dobrova-Krol et al, 2010A
Total (95% CI)
Heterogeneity: Chi² = 0.05, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 3.38 (P = 0.0007)
Mean
94.6
-0.61
-1.86
SD
14.7
1.06
1.3
Total
11
15
13
39
Mean
103.7
0.12
-0.89
SD
9.4
0.78
0.72
Total
15
16
11
42
Weight
32.0%
38.9%
29.1%
100.0%
IV, Fixed, 95% CI
-0.74 [-1.55, 0.07]
-0.77 [-1.50, -0.03]
-0.87 [-1.72, -0.02]
-0.79 [-1.25, -0.33]
HIV positive HIV negative Std. Mean Difference Std. Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
HIV positive HIV negative
Figure 7: Height for Age among HIV positive and negative children 
 
Head Circumference 
Boivin (1995) was the only study to report head circumference with 26 participants: 11 HIV 
positive and 15 HIV negative. There was no significant difference in the head circumference of 
HIV infected children (SMD -0.67, 95% CI -1.47, 0.13, p = 0.10). 
 
Subgroup Analyses 
Cognitive Developmental mean quotient for studies that measured development using the 
Bailey Scales 
Three studies that used Bailey Scales (Chase 2000; Knight 2000; and Lindsey 2007) were 
analysed in a sub group to assess direction of findings. Studies were homogenous: Chi² = 0.84, df 
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= 2 (p = 0.66); I² = 0%. HIV infected children scored -0.59 significantly lower than HIV positive 
children (SMD 95% CI-0.76, -0.41, p < 0.00001). 
 
Study or Subgroup
Chase et al., 2000
knight et al., 2000
Lidsey,2007
Total (95% CI)
Heterogeneity: Chi² = 0.84, df = 2 (P = 0.66); I² = 0%
Test for overall effect: Z = 6.57 (P < 0.00001)
Mean
96.8
76.1
84
SD
19.2
26
16
Total
80
20
57
157
Mean
105
94.7
92
SD
15.2
22.3
12
Total
362
25
593
980
Weight
51.1%
8.2%
40.7%
100.0%
IV, Fixed, 95% CI
-0.51 [-0.76, -0.27]
-0.76 [-1.37, -0.15]
-0.64 [-0.92, -0.37]
-0.59 [-0.76, -0.41]
HIV positive HIV negative Std. Mean Difference Std. Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
HIV positive HIV negative
Figure 8: Cognitive developmental mean quotient for studies that measured development 
using the Bailey Scales 
 
Motor developmental mean quotient for studies that measured development using the 
Bailey Scales 
A subgroup analysis of studies that used Bailey Scales (Chase 2000; Knight 2000; and Lindsey 
2007) was used to explore heterogeneity. Heterogeneity between studies was not important: Chi² 
= 0.06, df = 2 (P = 0.97); I² = 0%). HIV infected children scored a significantly lower motor 
mean quotient in studies that used Bailey Scales -0.62 SMD 95% CI, -0.79, -0.44, p< 0.00001). 
Study or Subgroup
Chase et al., 2000
knight et al., 2000
Lidsey,2007
Total (95% CI)
Heterogeneity: Chi² = 0.06, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 6.87 (P < 0.00001)
Mean
97.7
79.8
80
SD
19.9
29.1
17
Total
78
20
57
155
Mean
108.3
94.6
89
SD
15.8
18.4
15
Total
359
25
593
977
Weight
50.1%
8.5%
41.3%
100.0%
IV, Fixed, 95% CI
-0.64 [-0.89, -0.39]
-0.61 [-1.22, -0.01]
-0.59 [-0.87, -0.32]
-0.62 [-0.79, -0.44]
HIV positive HIV negative Std. Mean Difference Std. Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
HIV positive HIV negative
Figure 9: Motor developmental mean quotient for studies that measured development 
using the Bailey Scales 
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Sensitivity Analysis results 
Cognitive development (Standard Mean Difference) 
Effecacy of ARV in reducing developmental delay was assessed by comparing studies which 
used ARV (Lindsey; Dobrova- Krol A; Dobrova-Krol B) therapy and those which did not (n=4) 
in a sensitivity analysis. Antiretroviral treatment studies did not show to be effective in reducing 
cognitive deficits (SMD -0.66 95%CI, -0.91, -0.40, p < 0.00001, heterogeneity: Chi² = 1.77, df = 
2 (P = 0.41); I² = 0%) compared HAART naive studies (SMD-0.47 95% CI,-0.66, -0.27, p < 
0.00001, heterogeneity: Chi² = 2.48, df = 3 (p = 0.48); I² = 0%). 
 
Motor Development (Standard Mean Difference) 
Sensitivity Analysis on studies that blinded the examiner (n=5) and those which did not blind the 
examiner (n=2) were done. Both results were significant but studies that blinded the examiner 
had higher difference (-0.76 SMD 95%CI, -0.95, -0.56, p< 0.00001),   heterogeneity Chi² = 4.70, 
df = 4 (P = 0.32); I² = 15%) than studies that did not report blinding (-0.62, 95% CI, -0.80, -0.43, 
p < 0.00001). Heterogeneity was not important: Chi² = 0.06, df = 1 (p = 0.81); I² = 0%. 
 
Weight for age 
Miller (1993) was the only trial with a birth weight and a sensitivity analysis of studies that used 
any other weight was used to explore heterogeneity. Studies showed homogenous results (-0.75 
SMD, 95%CI, -1.03, -0.46, P < 0.00001), heterogeneity of : Chi² = 0.96, df = 3 (p = 0.81); I² = 
0%.  
 
 
 
Stellenbosch University http://scholar.sun.ac.za
32 
 
Discussion   
Summary of main results   
This comprehensive assessment of available literature identified 15 studies that provided 
objective assessments of cognitive/ and motor outcomes/ and anthropometric outcomes in HIV 
infected children compared with HIV negative children.  This included a total of 3 086 
participants: (598 HIV positive and 2 486 HIV negative).  Studies included 9 prospective and 3 
retrospective cohort studies and 3 cross sectional.  A total of 13 studies assessed ART naive 
participants and 2 studies assessed children on HAART. Participants had a mean age or were 5 
years of age and less using various scales of developmental assessment.  HIV infected children 
were 2.45 times at higher risk of developing cognitive developmental delay than HIV negative 
children (RR, 95% CI, 1.95, 3.07, p < 0.00001). 
Infected children scored -0.54 less than HIV negative children (SMD 95% CI, 0.70, -0.39, p < 
0.00001) for cognitive development and -0.68 in motor development (SMD 95% CI, 2.19, 3.99, 
p < 0.00001).  The risk of motor developmental delays was 2.95 times more likely in HIV 
positive children compared to HIV negative children (RR 95% CI, 2.15, 4.18, p< 0.00001). 
However, more evidence is needed on evaluating children on HAART to substantiate its effect 
on cognitive and motor deficits in HIV infected children aged less than 5 years. 
Overall completeness and applicability of evidence   
We identified 336 studies and 15 met the inclusion criteria with a total of 3 086 participants.  A 
meta-analysis in this review examined cognitive and motor outcomes using standardised 
assessments. 
The results of this review substantiate the evidence that HIV infection affects cognitive and 
motor development in children negatively.  Deficits were mostly manifested in motor 
development in terms of severity.  
Weight for age and height for age reported sufficient data to be pooled in to a meta-analysis.  A 
significant growth reduction in height for age and weight for age in HIV infected children was 
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evident.  However, physical growth delays of HIV-infected children were not significant in 
comparison to HIV-negative children in head circumference and weight for height. 
Heterogeneity between studies ranged from 0 to 42% in cognitive and motor outcomes and 0% 
to 47% in anthropometric outcomes. Subgroup analysis with Bailey Scales showed homogenous 
results.  
The design of the study influenced investigations of neurological impact of HIV in children; the 
delay in cross sectional studies was higher than that of cohort studies for 3 out of 4 outcome 
measures. This may suggest that cross sectional studies may overestimate the developmental 
delay or confounding factors may be at a peak at the point of measurement. 
Most assessment tools for cognitive and motor development were developed and validated in 
USA and Europe and only 3 studies from Africa (Abubakar 2010; Boivin 1995; Msellati 1993) 
in this review developed their own assessment tool. African children scored lower (Van Rie, 
2007) than USA children on studies that used internationally validated tools and this suggests 
modification of assessment tools to assess African children within their cultural context.  
The long term effect of HIV infection on neurological involvement is difficult to ascertain 
because of high attrition rates ranging from 0% (Abubakar 2007) to 58% cumulative mortality 
(Msellati 1993).  HIV infected children died before their second birthday.   
Only two studies (Lindsey 2007; Dobrova-Krol 2010) in this review assessed participants on 
HAART.  These 2 studies showed that children on HAART scored lower than HAART naive 
children in a sensitivity analysis. The significance of these results is difficult to ascertain due to 
limited studies and confounding factors identified (Dobrova-Krol 2010, assessed 1 group of 
institutionalised children). Developmental delays in HIV infected children can also be caused by 
an adverse rearing environment (Kullgren et al., 2004, p. 251).  HAART treatment has been 
proven to prolong the lives of HIV infected children (Scalco, 2004, p. 25).  More evidence is 
needed to determine its effect in reducing developmental delays and for longitudinal studies with 
minimal loss to follow up. 
Studies which controlled at least 1 confounding factor (socioeconomic status, preterm delivery, 
maternal drug use and home and environment) were appraised in the comparability section, 
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however studies did not control all four confounding factors which may also affect the 
development of children and may result in an overestimation of the developmental deficits.  
Limitations 
 Five studies compared HIV positive children with seroreverters making it difficult to 
control the effects of maternal illness.   
 Studies that used a mean age of less than 5 years (Boivin 1995; Dobrova-Krol 2010) were 
included and some of the children in those studies may be older than 5 years. 
 Efforts at contacting four authors to impute quantified results for the outcomes (two 
presented in graphs, one analysed with and a t test and one in z scores for anthropometric 
outcomes) proved unsuccessful as some of the email contacts were no longer active for 
two authors and two did not respond.  One author was contacted for translation of an 
Italian study to English and the study could not be translated (Piazza, 1995). 
 The systematic review was based on relatively a few articles and methodological 
weakness could influence conclusions of this study. 
 Considerable variability across the studies in terms of methods used and reporting of 
findings could possibly limit comparison of results. 
 
Quality of the evidence  
Four studies were regarded as of high quality. A total of nine studies blinded the examiners and 
twelve studies performed a baseline examination. Loss to follow up was accommodated by 
choosing the first assessment when all participants were present. Controlling for confounding 
was done by fourteen studies with one or more factors which may affect neurodevelopment. A 
total of ten studies used an intention to treat analysis.  
 
Agreements and disagreements with other studies or reviews   
This systematic review provides evidence that HIV delays cognitive, motor development weight 
for age and height for age in children aged 5 and less than 5 years. A met analysis was done in 
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conjunction with critical methodological quality appraisal to provide more precise, less biased 
and reliable evidence. 
The results of this review correspond to those by Abubakar et al. (2008, p.880), who established 
that motor development is the most apparent in terms of severity, early onset and persistence 
across age groups. White et al. (1995:) reported that the median rate of neuropsychological 
impairment based on test performance was 35% in HIV positive and 12% in HIV negative 
patients in a review of 57 studies. However, Newman et al. (1995, p.1211) found that there was 
no significant variation in the neuropsychological testing results amongst symptomatic and 
asymptomatic participants, as well as baseline impairment in seropositive participants. 
 
Author's conclusions 
HIV infected children are slower in aspects of cognitive and motor development compared to 
their HIV negative counterparts. They also showed delays in anthropometric outcomes; weight 
for age and height for age. Study design influenced results of the studies with children scoring 
more on cross sectional than cohort studies. There is still need to develop culturally appropriate 
or standardise neurodevelopment tools as most African studies still rely on international tools. 
More evidence is needed on the effectiveness of HAART in reducing cognitive and motor delay. 
Controlling for confounding in observational studies is a big problem which needs urgent 
attention and confounding may lead to over estimation of effects. Sub group analysis with bailey 
scales of infant development resulted in homogenous results; this may suggest further reviews on 
variety of neurodevelopment assessment tools. These results highlight the necessity of cognitive 
and motor interventions for HIV infected children focusing on cognitive and motor skills to 
improve their development and quality of life. 
 
Implications for nursing practice 
The HIV epidemic is growing and may result in neurodevelopmental delays in infected children. 
Neurodevelopmental assessments should be a compulsory assessment to all HIV infected 
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children as routine screening protocols. This will ensure monitoring disease progression and 
effects on the nervous system for immediate, appropriate, referral for further treatment. Staff 
training and continuous education programmes on screening and conducting developmental tests 
may improve identification of delays on time. Screening tools should be improved and their 
effectiveness increased by simplifying the current tools to fit into different cultural contexts. 
Developmental tools developed in Africa should be tried in developed countries to assess their 
reliability and validity. 
 
Implications for nursing education and research 
The incidence of HIV is highest in Africa; therefore more research needs to be conducted on its 
effects on neurodevelopment.  The effectiveness of HAART in reducing neurodevelopmental 
deficits needs more research in Africa. Other interventions such as massage therapy need to be 
evaluated in the African context for their effectiveness in increasing cognitive, motor 
development and cd4 count. 
Anthropometry should be performed in all studies conducted on children. More research in 
Africa may then facilitate the comparison of the results with those of other parts of the world. It 
is imperative to develop or standardise the current application of neurological examinations to fit 
into the African context. 
 
Dissemination of results 
To conclude the research process a report was compiled and submitted as a thesis at  
Stellenbosch University. The results of the review will be presented at local and conferences in 
the department of health and education. Copies will be distributed in the University library and 
the review will be published in peer reviewed accredited journals. 
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Appendix 1 
Results of Included Studies 
First author, Year, 
Country 
Confounding factors controlled  
Lost to follow up 
Developmental 
Outcomes 
1.Abubakar, 2009 
Kenya  
age, gender, socio economic status maternal 
education, home and environment 
Weight for age 
psychomotor  
2.Aylward, 1992 
USA 
History of IV drug usage, home and environment, 
maternal al age and education. 
6% lost to follow up 
Cognitive, Motor, 
Language 
3.Boivin, 1995 
Zaire 
Age, gender, educational level of the mother, and 
general economic status of the home environment. 
Cognition/ Language, 
Motor, anthropometric 
outcomes 
4. Chase, 2000 
USA 
Hard drugs exposure, prematurity, socio economic 
status, maternal education 
13 died in HIV positive group. Unexplained loss to 
follow up 
Cognitive and Motor 
development 
5. Dobrova-Krol, 
2010 
Ukraine 
age, socioeconomic status , maternal age, home and 
environment 
Cognitive performance, 
theory of mind, 
anthropometric outcomes 
6. Drotar, 1997 
Uganda 
Full-term babies, no birth complications, genetic 
impairments, or gross neurologic impairments , home 
and environment. .No infants received zidovudine 
(AZT). 
56% died in HIV + and 1 in control group* 7% lost 
to follow up 
Cognitive and motor 
development 
Information processing 
ability  
7. Fishkin, 2000 
USA 
Socio economic status, ethnicity, prenatal drug 
exposure 
3.75% died after data collection 
Gross  motor and cognitive 
development 
8. Gay, 1995 
Haiti 
Ethnicity, maternal prenatal drug use, maternal 
Separation and death, and birth history.  4 premature 
babies excluded  
Cognitive and Motor 
development 
9. Knight, 2000 
USA 
prenatally drug exposed. 2 neurological and 2 
developmental evaluations. For inclusion 
Cognitive and motor 
development 
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10. Lindsey, 2007 
USA 
Maternal ART exposure & history of IV drug use, 
birth weight, educational level of the primary care 
giver. Univariate analysis of covariates. 
HIV +: 13% and 6%HIV negative: l5 % lost to 
follow up.  
Cognitive and Motor 
development 
11. McGrath, 2006 
Tanzania 
Matched by socio economic status, age and gender, 
prematurity, marital status. 
LTFU: 29% HIV- and 27%HIV+ .11 %  died  
Cognitive and Motor 
development 
12. Miller, 1993 
USA 
Age, socioeconomic backgrounds. No  antiretroviral 
No loss of follow up 
anthropometry : weight 
13. Msellati, 2003 
Rwanda 
Neurologic developmental assessments. Comparable 
socioeconomic status. 
13.9% died 
Motor development 
14. Tahan 2006 
Brazil 
Age, one neurological evaluation  Cognitive and Motor 
development 
15. Van Rie , 
2007. Republic of 
Congo 
 Matched with age and gender, 
Socioeconomic status. Health status of the parents 
was assessed @ enrolment. 
Mental, cognitive, 
language and motor 
development 
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Appendix 2  
Eligibility Form 
 
Eligibility form 
Author: eg, Boivin: Year Published, 1995 
Types of study  Tick 
 Observational trials   
Types of participants  
HIV positive children less than 5 years  
Outcomes    
Cognitive development  
Motor development   
Weight for age,  
 Weight for height,   
Height for age   
Head circumference.  
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Appendix 3 
Characteristics of Excluded Studies 
 
 
 
 
 
 
 
First author (in 
alphabetical 
order) 
Study design Reason for contact Reason for  Exclusion 
Belman, 1996 Prospective cohort No number of children delayed and not 
delayed or means and standard 
deviation of MDI and PDI in HIV+ and 
HIV negative children 
Delivery of Email failed 
Blanchette et al, 
2001. Toronto 
Cross sectional 
study 
No number of children delayed and not 
delayed or means and standard 
deviation of MDI and PDI 
Author did not respond 
Bobat, 2001. 
South Africa 
prospective, 
hospital-based, 
cohort study 
Anthropometric outcomes presented in 
Z scores 
Email delivery failed 
Bruck, 2001.  
Brazil 
Prospective 
Longitudinal cohort 
Author not contacted Study published by 
Tahan 2006 and included 
in the review 
 Nozyce et al, 
1994. USA 
Prospective cohort 
Study 
Results presented in graphs and no 
means +SD 
Author did not respond 
Piazza et al, 1994. 
Italy 
Prospective Cohort Study in Italian Author responded Italian 
study could not be 
translated to English. 
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Appendix 4  
Quality Assessment of Included Studies  
 
New castle for cohort studies 
First author Selection Comparability Outcome 
Aylwald 
 
 
 
 
 
 
Total 7 
Recruited from inner city referral hospital, 
Exclusion criteria; Preterm’s/premature 
infants excluded  * 
Study group tested for HIV* 
Community controls* 
No neurological exam at entry 
 
*** 
Matched with age pre 
terms excluded and iv 
and substance abuse 
interpreted.  
 
 
 
** 
Assessor blinded and 
BSID used* 
2year follow up* 
LFTU with selective 
reporting. 172enrolled, 
101, enrolled, 10 lost to 
follow up and 5 excluded. 
71??? 
** 
 
Boivin 
 
 
 
 
Total 8 
Recruited from a previous study and hospital 
records  and author mentioned 
representativeness in community, exclusion 
criteria, sick children * 
Community controls used* 
No neurological exam at entry 
Tested for HIV* 
*** 
Matched with age, 
gender, educational 
level of mother and 
socio economic status  
 
 
** 
examiners were blinded 
with K ABC* 
2 year follow up* 
LTFU all participants 
analysed* 
 
*** 
Chase 
 
 
 
 
 
Total 8 
All participants enrolled at birth and 
recruitment of  mothers during Pregnancy, 
Exclusion criteria multiple births and infants 
born to mothers already enrolled. * 
Controls from the same community * 
A neurological exam done at entry level* 
An HIV test was done* 
**** 
Matched with age, 
socio economic status, 
and prenatal drug use, 
maternal educational 
level prematurity 
incorporated as 
covariate in the 
modeling process. 
** 
No blind assessment BSID 
2 year follow up* 
13 in HIV group died 
All children were 
analysed** 
Multivariate analyses 
done. HIGH quality 
** 
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Drotar 
 
 
 
 
 
 
 
Total 8 
Recruitment done during pregnancy and 
children enrolled at birth, exclusion  
preterm’s * 
Randomised community controls * 
Gross neurologic impairments on physical 
examination were excluded* 
Study participants  were tested for HIV* 
 
**** 
Matched with age and 
gender, maternal 
education level and 
only full term babies 
were enrolled.  
Stratifying group 
means for home and 
environment 
HIGH quality 
** 
physicians blinded with 
BSID* 
2years follow up* 
56% died in HIV + and 1 
in control group* 7% lost 
to follow up 
 
 
** 
 
Fishkin 
 
 
 
 
 
 
Total 7 
 Represent a larger population of HIV 
infected children, * 
Community controls healthy  children at 
child wellness centre* 
Medical records were reviewed for 
neurological development 
Study participants tested for HIV * 
*** 
Matched with age, 
gender, ethnicity, 
prenatal drug exposure. 
 
 
 
 
** 
Data collector was blinded 
to WPPSI-R performance 
* 
No follow up statement 
13 children died by the 
time data was collected in 
the HIV +group but all 
children were analysed* 
** 
Gay 
 
 
 
 
Total 8 
Maternal  recruitment during pregnancy* 
Community controls, Exclusion criteria 
maternal use of illicit drugs* 
Initial Neuro assessment as  inclusion 
criteria* 
Participants tested for HIV* 
 
**** 
Matched by maternal 
prenatal 
substance exposure, 
ethnicity, 
socioeconomic 
Status (SES), and 
maternal separation 
and death.  
** 
No blinding with  BSID 
Follow up 2 years* 
 (40.6% and 51.5% of the 
data for infected and 
uninfected infants, 
respectively), 
All children analysed* 
** 
Knight 
 
 
 
 
 
Total 8 
Retrospective study from referral hospital on  
children with development and neurological 
assessments * 
Community controls also referred to the 
hospital  family based care* 
Retrospective study with two assessments 4 
to 12 months apart 
Participants tested for HIV* 
Matched by age,  
gender, prenatal drug 
exposure, ethnicity 
status 
 
 
 
 
Psychologists were blinded 
with BSID* 
Two developmental tests 4 
to 12 months apart* 
All children were 
analysed* 
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*** ** *** 
Lindsey 
 
 
 
 
 
Total 8 
Maternal  recruitment during pregnancy for  
Arv study, no children excluded* 
Community controls* 
Neurological assessment done at baseline* 
Participants tested for HIV* 
 
**** 
Maternal ART 
exposure, maternal 
history of IV drug use, 
birth weight, 
educational level of the 
primary care giver** 
Confounding factors- 
Univariate analysis 
HIGH QUALITY** 
No blinding  with BSID* 
3 months intervals for 24 
months* 
13%  HIV – and  6% HIV 
+ LTFU* 
 
** 
Mc Grath 
 
 
 
 
Total 7 
Maternal recruitment during pregnancy, no 
children excluded  * 
Community controls * 
No neurological assessment at baseline 
Participants tested for HIV baseline* 
 
 
*** 
Participants were 
matched by socio 
economic status, age 
and gender, 
prematurity. 
 
** 
 
examiners were blinded 
with BSID* 
6 months intervals for 18 
months* 
29% HIV- and 27%HIV+ 
LFTU 
Inconclusive results of 
LFTU. Author contacted 
** 
Miller 
 
 
 
 
Total 8 
Retrospective review of data from a referral 
hospital for children with history of HIV 
infection* 
Community controls(Seroreverters)* 
Birth weights taken* 
HIV tested and available on records* 
**** 
matched by weight and 
gestation age 
 
 
 
 
** 
Birth  weights extracted 
Length of follow up 
No loss to follow up* 
** 
 
 
* 
Msellati 
 
 
 
 
 
 
Total 7 
Maternal recruitment at birth and 
Community controls, plus exclusion criteria 
of children with indeterminate status** 
No initial neurological assessment 
Participants tested for HIV* 
 
*** 
Matched with age and, 
prematurity and 
gestational age, Socio 
economic status.  
stratifying  of 
confounding done** 
HIGH QUALITY 
** 
physician blind to status 
with part of (Denver score 
and Illingworth’s)* 
followed up for 2 years* 
cumulative mortality in 
HIV+ group was 58% by 
the end of 24months 
** 
Tahan 
 
Recruited at Paediatric  Infectology   
and Neurology outpatient clinics of the 
Matched with age 
The exclusion criteria 
Denver and 
CAT/CLAMS* 
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Total 8 
Clinical Hospital of UFPR, exclusion criteria 
of 2 or more normal neurological 
assessments* community controls* 
initial neurodevelopment as inclusion 
criteria* 
Participants tested for HIV* 
**** 
were 
neurological 
complications,  
, 
 
* 
7 years follow up* 
All children analysed* 
 
 
 
*** 
 
 
 
 
 
Quality Assessment ( cross sectional) 
Primary 
Author 
Selection Comparability Exposure 
Abubakar 
 
 
 
 
Total 8 
Tested for HIV* 
Cases were obviously HIV positive children 
speaking the local language* 
Community controls who were randomly 
excluded* 
Controls  defined as healthy and free from 
disease* 
**** 
Matched by age, 
gender, socio economic 
status maternal 
education* 
 
 
** 
Examiners were 
blinded* 
Both groups assessed 
by kififi scale * 
 
 
** 
Dobrova- 
Krol 
 
 
 
Total 7 
HIV result available on records* 
Cases HIV positive children* 
Community controls* 
Controls defined as healthy and free of disease 
 
* 
Matched on  age, 
socioeconomic status , 
maternal age  
 
 
** 
No blinding 
(Snijders-Oomen 
Nonverbal 
Intelligence Test– 
Revised [SON–R])  
k for both groups 
* 
Van Rie 
 
 
 
 
HIV-infected children were identified 
through a paediatric HIV care and treatment 
program- record linkage* 
obviously  representative of HIV infected 
children, sick children excluded* 
Matched with age and 
gender 
Clinical and 
anthropometric data, 
socioeconomic status 
N o blinding 
Both groups Assessed 
with BSID* 
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Total 7 
Community controls* 
Controls  defined as absence of an illness that 
interferes with daily activities* 
**** 
 
and health status of the 
parents were assessed 
enrolment. 
** 
 
 
 
* 
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Appendix 5 
 Data Extraction of Included Studies 
Abubakar et al., 2009 Cross sectional study: 1 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described:  
method used: home visits, interviews 
 
 
 
 
Relevant confounders described: Preterm birth, substance abuse during pregnancy, home and 
environment, age and  disease stage  
  
Method used for controlling for confounding 
 At design stage:  matching 
 
 
 
 
  Variables on which subjects matched: Age 
 At analysis stage:        stratification 
                                                  multivariable regression 
                                                  propensity scores (matching) 
  propensity scores (multivariable regression) 
 
 
 
 
 
 
 
 
 
Blinding  yes 
 
Data extraction 
 
Characteristics of participants 
 
Characteristic Con Exposed Unexposed Diff’t 
Age  aged 6 to 35 months  6–35 months,  9 mo 
Sex  160:159 17: 14  
 Entire study  Intervention Control 
Number of participants identified 367 31 319 
Number of participants: excluded/lost to 
follow-up  
 none None 
Number of participants included    
All participants accounted for? yes   no    
Eligibility / inclusion / exclusion criteria  
 
 
 
HIV positive aged 6 
to 35months 
HIV negative aged 6 to 
35 months 
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Living in home / institution   Home Home  
Rural / urban setting  rural Rural  
HAART or any Treatment  Not mentioned Not mentioned  
Place of examinations  Exams done @home Exams done @home  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery  Not mentioned Not mentioned  
tested for HIV/ Healthy  yes No  
 
 
Aylwald et al., 1992 cohort Study: 2 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: questionnaire interviews and urine  
toxicology report 
  
Relevant confounders described: IVI substance abuse, age, home environment, socioeconomic status   
 
 
Method used for controlling for confounding 
At design stage:  matching 
Variables on which subjects matched: Infants age, maternal education and age 
 
 
 
 
 
 
 At analysis                                                                           ZV 
`stage:         stratification 
                                       multivariable regression 
                                       propensity scores (matching) 
                                       propensity scores (multivariable regression) 
  
 
 
 
Blinding: examiners were blinded   
 
Data Extraction 
 Entire study  Intervention Control 
Number of participants identified 172   
Number of participants: excluded/lost to 
follow-up  
10 + 5indefinite status 3 7 
Number of participants included 96 12 45hiv +39 
exposed 
All participants accounted for? yes     no    
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Characteristics of participants 
 
Characteristic Con HIV positive HIV negative Diff’t? 
Age  Mean: 10.2months Mean: 10.2months   
Sex: male: female  7:12 24:45  
Living in home / institution (foster care)  4:12 15:45  
Rural / urban setting  urban Urban  
Haart or any Treatment  Not mentioned Not mentioned  
Substance abuse during pregnancy  8:12 41:45  
Preterm delivery  Not mentioned Not mentioned  
tested for HIV  yes No  
 
 
 
Boivin et al., 1995 cohort, Study:3 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: 
Home visits and evaluations 
 
 
 
Relevant confounders described: socio economic status, confirmed HIV status, age   
Method used for controlling for confounding 
At design stage:  matching 
Variables on which subjects matched: Infants age, maternal education and age, mode of delivery 
 
 
 
 
 
 
 
At analysis stage:    stratification 
                                 multivariable regression 
                     propensity scores (matching) 
                     propensity scores (multivariable regression) 
  
 
 
 
Blinding  yes 
 
Data extraction 
Eligibility / inclusion / exclusion criteria  HIV positive HIV negative 
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Characteristics of participants 
 
Characteristic Conf HIV POSITIVE HIV NEGATIVE Diff’ 
Age  54.8 54.8 hs 
Sex: male: female  Not mentioned Not mentioned  
Living in home / institution   Not mentioned Not mentioned  
Rural / urban setting  urban Urban  
Exams done @ hospital  yes Yes  
Haart or any Treatment  No Haart No Treatment  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery (mean week gestation)  Not mentioned Not mentioned  
tested for HIV/healthy     
 
 
 
Chase et al., 2000 Cohort Study:4 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: interviews and questionnaires and urine 
toxicology test, prenatal history, ultrasound and physical examination. 
  
Relevant confounders described: Age, ethnicity, gender, prenatal drug use, prematurity, socio 
economic status 
  
 Entire study  Intervention Control 
Number of participants identified 93 52 41 
Number of participants: excluded/lost to 
follow-up  
52 41 11 
Number of participants included 41 11 15 sero and 15 neg 
All participants accounted for? yes     no    
Eligibility / inclusion / exclusion criteria  
 
HIV positive, with a 
neurological 
assessment 
HIV negative with a 
neurological 
assessment 
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Method used for controlling for confounding 
 At design stage:  matching 
Variables on which subjects matched: Age, ethnicity, gender, prenatal drug exposure, prematurity, 
socio economic status 
 
 
 
 
 
 
 
 At analysis stage:     stratification 
                                   multivariable regression 
                                   propensity scores (matching) 
                                   propensity scores (multivariable regression) 
List confounders controlled for under Data extraction, characteristics of participants: Prematurity, 
prenatal drug use 
 
 
 
 
 
 
 
 
Blinding  N0 
 
Data extraction 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff’ 
Age: mean  Birth birth  
Sex: male: female  41:36 173: 171  
Living in home / institution   Not mentioned Not mentioned  
Rural / urban setting  Urban urban  
Hospital Assessments  Yes yes  
Haart or any Treatment  Not mentioned Not mentioned  
Substance abuse during pregnancy  55.8% 39.2%  
Preterm delivery (M & SD)  22% 17%  
 Entire study  Intervention Control 
Number of participants identified 1016 191 825 
Number of participants: excluded/lost to 
follow-up  
595 114 485 
Number of participants included 421 77 344 
All participants accounted for? yes     no    
Eligibility / inclusion / exclusion criteria  
 
>3 neurological 
exams included 
> 3 neurological 
exams included 
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Tested for HIV/ Healthy  Yes yes  
Death  13died 3 excluded 0  
 
 
 
 
Dobrova-Krol et al., 2010 Cross sectional study: 5 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: excluded children with fetal alcohol 
syndrome 
  
Relevant confounders described: socio economic status, age, fetal alcohol syndrome   
Method used for controlling for confounding 
At design stage:  matching 
Variables on which subjects matched: Infants socioeconomic status, maternal age, sex,  
 
 
 
 
 
At analysis stage:   stratification 
                                multivariable regression 
                    propensity scores (matching) 
                                propensity scores (multivariable regression) 
  
 
 
 
Blinding  no 
 
Data extraction 
 
 
 
 
 
 
 Entire study  Intervention Control 
Number of participants identified 64 29 35 
Number of participants: excluded/lost to 
follow-up  
6 1 5 
Number of participants included 58 28 30 
All participants accounted for? yes     no    
Eligibility / inclusion / exclusion criteria  HIV positive HIV negative  
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Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  52.145 42.81  
Sex: male: female     
Living in home / institution   16 13  
Rural / urban setting  urban urban  
Haart or any Treatment  yes No Haart  
Substance abuse during pregnancy  Exclusion criteria Exclusion criteria  
Preterm delivery (M & SD)  Family: -1.15 (1.21) 
institution -
1.36 (0.56) 
Family: -0.32 (0.99)  
institution-0.81 
(0.61) 
 
tested for HIV/healthy  yes no  
 
 
 
Drotar et al., 1997 Cohort Study: 6 
 
Assessment of how researchers dealt with confounding: Excluding preterm’s,  yes no 
Method for identifying relevant confounders described:  neurologic and physical exam, 
Assessment of home and environment 
  
Relevant confounders described: Only full-term infants without significant birth complications or 
neurologic or genetic impairments based on newborn physical examination were 
enrolled 
  
Method used for controlling for confounding 
 At design stage:  matching 
Variables on which subjects matched: Age, ethnicity, gender, prenatal drug exposure 
At analysis stage:         stratification 
                          multivariable regression 
                          propensity scores (matching) 
                          propensity scores (multivariable regression) 
Comparing group means was used to assess the home environment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blinding yes  
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Data extraction 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  birth Birth  
Sex: male: female  32:29 62:53  
Living in home / institution   16 13  
Rural / urban setting  urban Urban  
Hospital Assessments  Yes Yes  
Haart or any Treatment  No Haart No treatment  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery (M & SD)  Full term Full term  
tested for HIV/ healthy  Yes No  
 
 
 
Fishkin et al., 2000 Retrospective cohort Study: 7 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described:  urine toxicology   
Relevant confounders described: Age, ethnicity, gender, prenatal drug use   
Method used for controlling for confounding 
 At design stage:  matching 
  
 
 Entire study  Intervention Control 
Number of participants identified 436 79  
Exposed;241  HIV- :116 
Number of participants: excluded/lost to 
follow-up  
26 18 deaths 7+1 deaths 
Number of participants included 410 61 Exposed:234  HIV-:115 
All participants accounted for? yes  no    
Eligibility / inclusion / exclusion criteria  
 
completed bailey 
exam 
completed bailey exam 
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Variables on which subjects matched: Age, ethnicity, gender, prenatal drug exposure  
At analysis stage:         stratification 
                          multivariable regression 
                          propensity scores (matching) 
                          propensity scores (multivariable regression) 
  
 
 
 
Blinding  no 
 
Data Extraction 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Di 
Age: mean  3 till 5 3 till 5  
Sex: male: female  Not mentioned Not mentioned  
Living in home / institution   No stats No stats  
Rural / urban setting  urban Urban  
Hospital Assessment  Yes Yes  
Haart or any Treatment  Not mentioned Not mentioned  
Substance abuse during pregnancy  Matched  Matched   
Preterm delivery (M & SD)  Not mentioned Not mentioned  
tested for HIV/ healthy  Reviewed from files No  
 
 
 
 Entire study  Intervention Control 
Number of participants identified 80 40 40 
Number of participants: excluded/lost to 
follow-up  
13 13deaths 0 
Number of participants included 80 40 40 
All participants accounted for? Yes     no    
Eligibility / inclusion / exclusion criteria  
 
HIV positive 3 to 5 
years 
HIV negative  3 till 5 
years 
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Gay et al., 1995   Cohort Study: 8 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: Urine toxicology test and questionnaire  
 
 
Relevant confounders described: ethnicity, maternal SES, maternal prenatal drug use, maternal 
separation and death, and birth history were controlled 
 
 
 
Method used for controlling for confounding 
 At design stage:  matching 
Variables on which subjects matched: Age, ethnicity, gender, prenatal drug exposure, 
prematurity, socio economic status 
 
 
 
 
 
 
 
 
 At analysis stage: stratification 
                               multivariable regression 
                               propensity scores (matching) 
                               propensity scores (multivariable regression) 
  
 
 
 
Blinding  no 
 
Data extraction 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  38.7 38.7  
Sex: male: female  53.6: 46.4% 43.9:54.1  
Living in home / maternal separation/death  7.1 8.2  
 Entire study  Intervention Control 
Number of participants identified 130 29 101 
Number of participants: excluded/lost to 
follow-up  
4 1 3 
Number of participants included 126 28 98 
All participants accounted for? Yes   no    
Eligibility / inclusion / exclusion criteria  
 
HIV positive non 
premature 
HIV negative non 
premature 
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Rural / urban setting  urban Urban  
Hospital Assessment  Hospital Hospital  
Haart or any Treatment  n=13   
Substance abuse during pregnancy  excluded Excluded  
Preterm delivery gestation  38.7 38.7  
tested for HIV  Yes Yes  
 
 
 
Knight et al., 2000 Cohort Study:9 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: questionnaire, Patients files   
Relevant confounders described: child age, gender, substance abuse, were controlled yes   
Method used for controlling for confounding: Age, gender, ethnicity, drug exposure 
 At design stage:  matching 
 
 
 
 
Variables on which subjects matched: child age, gender 
 
  
At analysis stage:  stratification 
                    multivariable regression 
                                propensity scores (matching) 
                                propensity scores (multivariable regression) 
  
 
 
 
Blinding  Yes 
 
Data extraction 
 
 Entire study  Intervention Control 
Number of participants identified 45 20 25 
Number of participants: excluded/lost to 
follow-up  
0 0 0 
Number of participants included 45 20 25 
All participants accounted for? yes   no    
Eligibility / inclusion / exclusion criteria  >2 neurological exams >2 neurological 
exams 
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Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age:   3 till 30 mo 3 till 30 mo  
Sex: male: female      
Living in home / primary caretaker not 
biological mother  
 Not mentioned Not mentioned  
Rural / urban setting  Urban urban  
Hospital Assessment  Yes Yes  
Haart or any Treatment  no data No treatment  
Substance abuse during pregnancy  14 16  
Preterm delivery mean : sd  Not mentioned Not mentioned  
tested for HIV/Healthy  Yes yes  
 
 
 
Lindsey et al., 2007 Cohort Study: 10 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders: questionnaire, urine toxicology  test   
Relevant confounders described: ethnicity, maternal SES, maternal prenatal drug use, ART 
exposure and birth history were controlled 
  
Method used for controlling for confounding 
 At design stage:  matching 
Variables on which subjects matched: Age, ethnicity, gender, prenatal drug exposure, 
prematurity, socio economic status 
 
 
 
 
 
 
 At analysis stage: stratification 
                                multivariable regression 
                                 propensity scores (matching) 
                                 propensity scores (multivariable regression) 
  
 
 
List confounders controlled for under Data extraction, characteristics of participants: drug 
exposure, prematurity. 
  
Blinding  no 
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Data extraction 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  <1 year < 1 year  
Sex: male: female  44:47 421:417  
Living in home / not staying with 
biological parent 
 5.1% 24.1%  
 
Rural / urban setting  Urban urban  
Hospital Assessment   Yes Yes  
Haart or any Treatment  On Haart No treatment  
Substance abuse during pregnancy  19.25 5.5%  
Preterm delivery <25000g  66.7% 82.8%  
tested for HIV  Yes Yes  
Maternal ART exposure  46.5% 96.6%  
 
 
 
Mc Grath et al., 2006 Cohort Study: 11 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: 
files reviewed for birth history and maternal cd4 
 
 
 
Relevant confounders described: maternal cd4 count and birth history were controlled    
 Entire study  Intervention Control 
Number of participants identified 929 91 838 
Number of participants: lost to follow-up   5 (6%) 107 (13%) 
Number of participants included 929 91 838 
All participants accounted for? yes     no    
Eligibility / inclusion / exclusion criteria  
 
Perinatally HIV 
exposed  
Perinatally HIV exposed 
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Method used for controlling for confounding 
At design stage:  matching 
Variables on which subjects matched: Age,  prematurity, socio economic status 
 
 
 
 
 
 At analysis stage:       stratification 
                                      multivariable regression 
                                      propensity scores (matching) 
  propensity scores (multivariable regression) 
 
  
 
 
 
Blinding  yes 
 
Data extraction 
 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age:   Birth till 18 months Birth till 18 months  
Sex: male: female (167:160)     
Living in home / institution  Not mentioned Not mentioned  
Rural / urban setting  Urban Urban  
Haart or any Treatment  Not mentioned Not mentioned  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery (75:327)     
tested for HIV  Yes Yes  
 
 Entire study  Intervention Control 
Number of participants identified 327 Not stated Not stated 
Number of participants: excluded/lost to 
follow-up 
11% 27% died 29% died 
Number of participants included 276 55 221 
All participants accounted for? yes   no    
Eligibility / inclusion / exclusion criteria  Bailey assessment, 
single delivery 
Bailey assessment,  
single delivery 
Blinding   Yes 
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Miller et al., 1993 Cohort Study:12 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: Hospital records   
Relevant confounders described: child cd4 count, prematurity,  and ARV exposure were 
controlled 
  
Method used for controlling for confounding 
At design stage: matching 
Variables on which subjects matched: Age,  prematurity, socio economic status 
 
 
 
 
 
 At analysis stage:  stratification 
                                 multivariable regression 
                                 propensity scores (matching) 
                                 propensity scores (multivariable regression) 
  
 
 
 
Blinding  no 
 
 
Data extraction 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  12mo 19  
Sex: male: female (167:160)     
Living in home / institution  Not mentioned Not mentioned  
 Entire study  Intervention Control 
Number of participants identified 71 52 37 
Number of participants: excluded/lost to 
follow-up  
   
Number of participants included 71 52 37 
All participants accounted for? Yes  no    
Eligibility / inclusion / exclusion criteria  HIV  +, receiving 
formula providing 
increased energy. 
Exposed, receiving 
formula providing 
increased energy. 
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Rural / urban setting  Urban Urban  
Hospital setting  Yes Yes  
Haart or any Treatment  Excluded Excluded  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery  19 15  
tested for HIV  Yes Yes  
 
 
 
 
Msellati et al., 1995 Cohort Study:13 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: 
Hospital records, questionnaire 
  
Relevant confounders described: child cd4 count, prematurity, maternal age and socio 
economic status, were controlled 
  
Method used for controlling for confounding 
At design stage:  matching 
Variables on which subjects matched: Age,  prematurity, socio economic status 
 
 
 
 
 
 
 At analysis stage:       stratification 
                                     multivariable regression 
                                     propensity scores (matching) 
  propensity scores (multivariable regression) 
Analysis was stratified by birth weight for prematurity or low birth weight 
 
 
 
 
 
 
Blinding  Yes 
 
 
Data extraction 
 Entire study  Intervention Control 
Number of participants identified 436 50  
218 
Number of participants: excluded/lost to 
follow-up  
24deaths + 32 
indeterminate 
11 deaths 13 deaths 
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Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  Enrolled at birth Enrolled at birth  
Sex: male: female      
Living in home / institution  Not mentioned Not mentioned  
Rural / urban setting  urban Urban  
Hospital Assessment  Yes Yes  
Haart or any Treatment  No treatment No treatment  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery   35 29  
tested for HIV/ defined as healthy  Yes Yes  
 
 
 
Tahan et al., 2006 Cohort Study: 14 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described: If yes, describe the method used: 
interviews, hospital records 
 
 
 
Relevant confounders described: child age were controlled The exclusion criteria were 
neurological complications, such as neonatal meningitis, congenital toxoplasmosis or 
cytomegalovirus, hypoxic isquemic encephalopathy, 
 
 
 
Method used for controlling for confounding 
 At design stage:  matching 
Variables on which subjects matched: HIV status   
Normal neurologic examination and age 
 
 
 
 
 
status  
Number of participants included 436 50 218 
All participants accounted for? yes    no    
Eligibility / inclusion / exclusion criteria  
 
HIV positive  HIV negative  
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 At analysis stage:   stratification 
                                 multivariable regression 
                                 propensity scores (matching) 
                                propensity scores (multivariable regression) 
  
 
 
 
Blinding  Yes 
 
Data extraction 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: mean  1month till 36 mo 1 month till 36mo  
Sex: male: female   Not mentioned Not mentioned  
Living in home / institution  Not mentioned Not mentioned  
Rural / urban setting  urban Urban  
Hospital Assessment  Yes Yes  
Haart or any Treatment  No treatment No treatment  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery   Not mentioned Not mentioned  
Tested for HIV/ healthy  Yes Yes  
Maternal ART exposure  Not mentioned Not mentioned  
 
 
 Entire study  Intervention Control 
Number of participants identified 172 88  
84 
Number of participants: excluded/lost to 
follow-up  
24.4%  42 
Number of participants included 172 88 84 
All participants accounted for? Yes     no    
Eligibility: exclusion criteria were neurological 
complications, such as neonatal, meningitis, congenital 
toxoplasmosis or cytomegalovirus, hypoxic isquemic 
encephalopathy. 
HIV positive  HIV negative  
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Van Rie., 2009 Cross sectional Study: 15 
 
Assessment of how researchers dealt with confounding yes no 
Method for identifying relevant confounders described:  Socioeconomic status was assessed by 
inquiring about access to running water, number of bedrooms, income, type of toilet, adequacy of 
income, and food. 
 
 
 
Relevant confounders described: Clinical and anthropometric data, socioeconomic status, and 
health status of the parents were collected at enrolment. 
 
  
 
Method used for controlling for confounding 
 At design stage: matching 
Variables on which subjects matched: child age, gender 
 
 
 
 
 
 
At analysis stage:    stratification 
                                 multivariable regression 
                                 propensity scores (matching)  
                                 propensity scores (multivariable regression) 
  
 
 
 
Blinding  no 
 
Data extraction 
 
 
Characteristics of participants 
 
Characteristic Con HIV POSITIVE HIV NEGATIVE Diff 
Age: median  45.7 45.6  
Sex: male: female   15:35 45:90  
Living in home / Orphaned  10 0  
 Entire study  Intervention Control 
Number of participants identified 160 35 35 Exposed  and 90 
HIV+ 
Number of participants: excluded/lost to 
follow-up  
0 0 0 
Number of participants included 160 35 90 
All participants accounted for? Yes  no    
Eligibility / inclusion / no exclusion criteria  HIV positive  HIV negative  
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Rural / urban setting  Urban urban  
Hospital Assessment  Yes yes  
Haart or any Treatment  HAART naive  No treatment  
Substance abuse during pregnancy  Not mentioned Not mentioned  
Preterm delivery   Not mentioned Not mentioned  
Tested for HIV/ Healthy controls  Yes yes  
Maternal ART exposure  Not mentioned Not mentioned  
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APPENDIX  6 
 
 NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE: CASE CONTROL STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure 
categories. A maximum of two stars can be given for Comparability. 
 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation  
b) yes, eg record linkage or based on self reports 
c) no description 
2) Representativeness of the cases 
                          a) consecutive or obviously representative series of cases   
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls  
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint)  
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for _______________  (Select the most important factor.)   
b) study controls for any additional factor   (This criteria could be modified to indicate specific                   
control for a second important factor.) 
 
Exposure 
1) Ascertainment of exposure 
a) secure record (eg surgical records)  
b) structured interview where blind to case/control status  
c) interview not blinded to case/control status 
d) written self report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls 
a) yes  
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b) no 
3) Non-Response rate 
a) same rate for both groups  
b) non respondents described 
c) rate different and no designation 
 
 
  
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE: COHORT STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome 
categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community   
b) somewhat representative of the average ______________ in the community  
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort  
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort  
3) Ascertainment of exposure 
a) secure record (eg surgical records)  
b) structured interview  
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes  
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor)  
b) study controls for any additional factor   (This criteria could be modified to indicate specific                   
control for a second important factor.)  
Outcome 
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1) Assessment of outcome  
a) independent blind assessment   
b) record linkage  
c) self report  
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest)  
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for   
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an                     
adequate %) follow up, or description provided of those lost)  
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  A 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
1 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
Not 
registered 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
8 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  9 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
10 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 11 
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and confirming data from investigators.  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
11 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
11 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  14 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
14 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
11 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
15 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
16 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
19 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  22 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 24-28 
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effect estimates and confidence intervals, ideally with a forest plot.  
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  24-28 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  24-28 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  28-31 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
32 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
34 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  35 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
No 
funding 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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